Genetic, Multiomic and Cytokine-based Mapping of Patients With Mastocytosis/Hypertryptasemia at the University Hospital of Zurich German: Mastozytose-Register: Datenerfassung Und Weiterverwendung Von Biologischem Material Von Patienten Mit Mastozytose, Welche am Universitätsspital Zürich Behandelt Werden
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- University of Zurich
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Demographics
Study Overview
Brief Summary
The study aims to summarize patients with mastocytosis and hypertryptasämia (without underlying mastocytosis or no bone marrow biopsy) in relation to demographic information, clinical progress and treatment courses. Biologic samples are collected from available routine diagnostics (serum, skin tissue, gut mucosa, bone marrow, and others) for further use in experimental research.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adult patients with mastocytsis/hypertryptasemia which are treated at the university hospital of Zurich
- •available informed consent
Exclusion Criteria
- •denied consent
Outcomes
Primary Outcomes
Demographics
Time Frame: 2010-2025
In the registry we collect patient's demographic data e.g. age, gender, comorbidities, smoking, preexisting atopic disease and other to look for associations to mast cell diseases.
Disease progression
Time Frame: 2010-2025
Patients will followed up over time to get more insight in disease progression.If there is progression detected (e.g. cutaneous mastocytosis to systemic mastocytosis or ISM to advanced forms) those cases will be carefully looked at to identify triggering factors and biomarkers.
Secondary Outcomes
No secondary outcomes reported